Results 131 to 140 of about 696 (142)

SERUM BIOMARKERS OF IMMUNOMODULATION DURING PEANUT EPICUTANEOUS IMMUNOTHERAPY (EPIT) IN PEANUT-ALLERGIC SUBJECTS

Annals of Allergy, Asthma & Immunology, 2018
Introduction Peanut allergy prevalence is increasing world-wide and currently no FDA-approved treatment is available. Epicutaneous immunotherapy (EPIT) with Viaskin Peanut (VP250) is being studied in peanut-allergic subjects using a novel single-dose (250 microgram peanut protein) patch.
Matthew Greenhawt, Warner Carr, Carla M. Davis, Phil Lieberman, S. Shahzad Mustafa, Anthony R. Green, P. Gramme, Romain Lambert, David M. Fleischer   +8 more
openalex   +2 more sources

Epicutaneous Immunotherapy (EPIT) Is Effective and Safe to Treat Peanut Allergy: A Multi-National Double-Blind Placebo-Controlled Randomized Phase IIb Trial

Journal of Allergy and Clinical Immunology, 2015
Sampson H.A.1, Agbotounou W.K.2, Thebault C.2, Ruban C.2, Martin L.2, Yang W.H. 3, Sussman G.L.4, Brown-Whitehorn T.F.5, Nadeau K.C.6, Cheema A.S.7, Leonard S.A.8, Pongracic, J.A.9, SauvageDelebarre C.10, Assa’ad A.H.11, De Blay F.12, Bird, J.A.13, Tilles S.A.14, Boralevi F.15, Bourrier T.16, Shreffler, W.G.17, Hebert J.18, Green T.D.19, Gerth Van Wijk
Hugh A. Sampson, Wence Agbotounou, Claude Thébault, Charles Ruban, Laurent Martin, William H. Yang, Gordon L. Sussman, Terri F. Brown‐Whitehorn, Kari C. Nadeau, Amarjit Cheema, Stephanie A. Leonard, Jacqueline A. Pongracic, Christine Sauvage, Amal Assa’ad, F. de Blay, J. Andrew Bird, Stephen A. Tilles, F. Boralévi, T. Bourrier, Wayne G. Shreffler, Jacques Hébert, Todd David Green, Roy Gerth van Wijk, André C. Knulst, Gisèle Kanny, Marek L. Kowalski, Lynda C. Schneider, Pierre Henri Benhamou, Christophe Dupont   +28 more
  +4 more sources

T.121. Epicutaneous Immunotherapy (EPIT): Proof of Concept with Various Allergens in Sensitized Mice

Clinical Immunology, 2009
Lucie Mondoulet, Vincent Dioszeghy, E Renard, Mélanie Ligouis, Christophe Dupont, Pierre‐Henri Benhamou   +5 more
openalex   +2 more sources

A Model of Eosinophilic Esophagitis (EE) and Villus Atrophy (VA) after Challenge in Mice Sensitized to Peanuts: Improvement by Epicutaneous Immunotherapy (EPIT)

Journal of Allergy and Clinical Immunology, 2010
Lucie Mondoulet, Vincent Dioszeghy, Mélanie Ligouis, Véronique Dhelft, Thibaut Larcher, Yan Chérel, Christophe Dupont, Pierre‐Henri Benhamou   +7 more
  +5 more sources

The Crucial Role Of The Stratum Corneum Superficial Layers During Peanut Epicutaneous Immunotherapy (epit)

Journal of Allergy and Clinical Immunology, 2011
Lucie Mondoulet, Vincent Dioszeghy, Mélanie Ligouis, Véronique Dhelft, Emilie Puteaux, Christophe Dupont, Pierre‐Henri Benhamou   +6 more
openalex   +2 more sources

Peanut Epicutaneous Immunotherapy (EPIT) In Peanut-Allergic Children: 18 Months Treatment In The Arachild Study

Journal of Allergy and Clinical Immunology, 2014
Christophe Dupont, T. Bourrier, F. de Blay, Lydie Guénard‐Bilbault, Christine Sauvage, Marie-Odile Cousin, Gisèle Kanny, Sophie Jarlot, Chantal Karila   +8 more
openalex   +2 more sources

Quantitative risk reduction through peanut immunotherapy: assessment for the peanut-allergic population undergoing epicutaneous immunotherapy (EPIT)

, 2018
Benjamin C. Remington
openalex   +2 more sources

Epicutaneous Immunotherapy (EPIT) Is Safe for the Treatment of Peanut Allergy in Allergic Patients

Journal of Allergy and Clinical Immunology, 2013
Wence Agbotounou, Laurent Martin, B. Dupont, I. Pascal, Cécile Vauléon, Pierre Henri Benhamou   +5 more
openalex   +2 more sources

Biomarker assessment after 12 months of peanut epicutaneous immunotherapy (EPIT) for peanut allergy

, 2018
Matthew Greenhawt
openalex   +2 more sources

Decrease of the Skin Local Immune Response to Peanut Following Peanut Epicutaneous Immunotherapy (EPIT) in Sensitized Mice

Journal of Allergy and Clinical Immunology, 2010
Vincent Dioszeghy, Lucie Mondoulet, Véronique Dhelft, Mélanie Ligouis, Christophe Dupont, Pierre‐Henri Benhamou   +5 more
openalex   +2 more sources